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ABSTRACT
Introduction: The dry and scaly skin of psori-
atic patients decreases the efficacy of ultraviolet
B (UVB) phototherapy. Different agents are used
to facilitate the transmission of light, but most
of these preparations are cosmetically unfavor-
able. We have tested a novel preparation con-
taining sodium hyaluronate and nicotinic acid
(UV Fotogel; Pernix Ltd.) with the double aim
to improve the efficacy of UVB phototherapy
and assess the cosmetic acceptability of the
preparation.
Methods: Ninety patients with plaque psoriasis
were enrolled in the study, of whom 44 received
narrow-band UVB (NB-UVB) phototherapy.
Prior to phototherapy, one side of the patient’s
body was treated with UV Fotogel while the
other side served as a control. The other 46
patients used the preparation at their homes
before regular sunbathing. The Local Psoriasis
Severity Index (L-PSI), cosmetic acceptability
and tolerability were recorded. The median
values with the 25th and 75th percentiles (25p
and 75p, respectively) were determined for the
UV Fotogel-treated and control sites and then
compared.
Results: The sides of the body to which UV
Fotogel was applied prior to NB-UVB pho-
totherapy had a significantly lower median
L-PSI score than the non-treated control sides at
the end of the treatment (1.0 [25p–75p: 0.0–2.0]
vs. 2.0 [1.0–3.0], respectively). The application
of UV Fotogel prior to sunbathing also led to a
significant decrease in L-PSI score. There was a
significant reduction in the median L-PSI score
of patients at the final visit compared to base-
line (2.5 [25p–75p: 1.5–3.5] vs. 6.0 [6.0–7.0],
respectively). Use of the preparation was not
accompanied by considerable adverse effects,
and the patients found it cosmetically accept-
able. Application of UV Fotogel prior to
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sunbathing was well tolerated by the patients,
and the cosmetic acceptability was also good.
Conclusion: UV Fotogel is potentially a useful
device for enhancement of the efficacy of pho-
totherapy in patients with psoriasis.
Keywords: Optical cleaning; Phototherapy;
Psoriasis; Ultraviolet B
Key Summary Points
Why carry out this study?
Phototherapy is a cornerstone in the
treatment of psoriasis; however, dry and
scaly skin decreases the efficacy of
phototherapy.
Many treatments used to improve the
efficacy of phototherapy have unfavorable
cosmetic properties or absorb ultraviolet
(UV) light, requiring higher UV doses to
be effective.
The aim of this study was to test whether
our novel medical device (UV Fotogel)
enhances UV phototherapy in psoriatic
patients.
What was learned from the study?
UV Fotogel considerably increased the
efficacy of UV phototherapy.
UV Fotogel was well tolerated by the
patients.
In contrast to compounds with similar
effects, UV Fotogel is cosmetically
acceptable.
INTRODUCTION
soriasis is a chronic autoimmune disorder, with
a prevalence in adults that varies from 0.91%
(USA) to 8.5% (Norway) [1], that considerably
decreases the health-related quality of life.
Although chronic plaque psoriasis, which is the
most common type of psoriasis, can be
diagnosed without major difficulties, the dis-
ease may still be underdiagnosed and under-
treated [2–4]. Several treatment options are
available for psoriasis. Topical therapy is typi-
cally chosen in mild to moderate manifesta-
tions, with corticosteroids [5], vitamin D3
analogues [6] and the combination thereof [7]
shown to be effective. In more severe cases,
systemic therapy is indicated, most commonly
with immunosuppressants (e.g., methotrexate,
cyclosporine), immune modulators (e.g.,
leflunomide), and biological agents [8–10]. In
addition to these different pharmacological
approaches, phototherapy is also considered to
be a safe and effective method for the treatment
of psoriasis. Many types of phototherapy use
ultraviolet B (UVB) light [11], with the most
effective wavelengths of the UVB spectrum
being between 310 and 320 nm. Wavelengths of
280–300 nm have a reduced therapeutic effect
and cause severe and unnecessary skin inflam-
mation [12–14]. The efficacy of phototherapy is
influenced by the reflection of UV light from
the skin surface, with dry, scaly skin reflecting
more UV light than healthy skin; accordingly, a
lower proportion of the radiation penetrates the
psoriatic lesions, thereby decreasing the thera-
peutic effect. Thus, the efficacy of phototherapy
might be improved by optimizing skin trans-
mittance and irradiating at a wavelength of
310–320 nm. Different topicals have been tested
with this goal (e.g., petrolatum, basis cream,
glycerine, olive oil, aqueous cream, Eucerin skin
products, Kamillosan ointment, paraffin oint-
ment, mineral oil [15–17]); however, some
preparations had unfavorable cosmetic proper-
ties or absorbed light in the UV spectrum,
requiring higher UVB doses to be effective.
The aims of this study was to test a novel
medical device containing polyethylene glycol
4000, nicotinic acid, and sodium hyaluronate
(UV Fotogel) for the enhancement of pho-
totherapy in psoriatic patients and to monitor
its efficacy and tolerability. The investigation
was performed in two parts. In Part I, the
preparation was applied before the patient
received narrow-band UVB therapy (NB-UVB),
and in Part II, UV Fotogel was used by the
patients prior to going sunbathing.
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METHODS
UV Fotogel
The gel comprises polyethylene glycol 4000,
nicotinic acid, sodium hyaluronate, and puri-
fied water. It is classified as a CE-marked Class I
medical device produced by Pernix Ltd. (Zalae-
gerszeg, Hungary).
Patients
Of the 90 patients enrolled in the study, 44
patients participated in Part I (24 males, 20
females; mean age 57.0 [range 26–82] years) and
46 participated in Part II (30 males and 16
females; mean age 57.2 [range 26–82] years). All
patients had plaque psoriasis. The inclusion
criteria were: minimum age of 18 years; ability
and intention to follow the instructions of the
investigator; communicated well with the study
personnel; indication for NB-UVB; disintegra-
tion and desquamation of stratum corneum; a
degree of desquamation of at least 2 points
according to the Local Psoriasis Severity Index
(L-PSI) score; and provided a signed informed
consent form. The exclusion criteria were:
application of any systemic and topical antip-
soriatic drugs (e.g., methotrexate, acitretin,
cyclosporine, biological therapies); use of
potentially photosensitizing drugs; anamnesis
of another disease accompanied by photosen-
sitivity; and progression of psoriasis during
previous NB-UVB or psoralen and UVA therapy.
The study was approved by the National
Institute of Pharmacy and Nutrition (Hungary)
(permission numbers: OGYE´I/723/2017 and
OGYE´I/28552/2017) and was performed in
accordance with the Helsinki Declaration of
1964 and its later amendments. Informed con-
sent was obtained from all participants.
Study Protocol
The aim of Part I was to test the efficacy of UV
Fotogel in patients receiving NB-UVB treatment
(Fig. 1). In this part of the study, the patients
were enrolled on day 0 (visit 1), at which time
they signed the informed consent agreement
and the baseline L-PSI scores were recorded. In
addition, the minimal erythema dose (MED)
was determined for each patient (range at
baseline 0.303–0.365 J/cm2). On the next day
(visit 2), the patients received their first pho-
totherapy treatment. One to three ipsilateral
plaques on the trunk and limbs and on both
sides of the body were chosen for treatment.
Randomization and application of UV Fotogel
was performed by a nurse specialized in pho-
totherapy. Prior to the NB-UVB treatment, UV
Fotogel was applied to one side of the body
only; the other side did not receive UV Fotogel.
The dose of the first treatment was 0.75 MED. In
subsequent treatments, the dose was increased
in increments of 25%. When considerable ery-
thema was present, the last dose was not
increased. NB-UVB was administered with a UV
Therapy System UV 1002 (Herbert Waldmann
GmbH & Co., Villingen-Schwenningen, Ger-
many). The cumulative total dose varied
between 2.555 to 27.77 J/cm2. NB-UVB treat-
ments were given three times a week, and no
other anti-psoriatic treatments were allowed
throughout the study period. When desqua-
mation ceased, the study was terminated for a
given patient. The study was also terminated
when patients achieved an L-PSI score of \ 4.
Fig. 1 Study protocol. Asterisks indicate the times of
narrow-band ultraviolet B (NB-UVB) treatments (Part I),
and the arrows indicate when the patient went sunbathing
(Part II). Although the patients were instructed to
sunbathe 3–5 times weekly, the actual number of times
sunbathing per week differed for each patient. In Part I,
the UV Fotogel was applied to parts of the body before
NB-UVB therapy; in Part II, UV Fotogel applied by the
patients prior to sunbathing
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The duration of treatment for all patients par-
ticipating in Part 1 was a minimum of 3 weeks
and not longer than 6 weeks.
The aim of Part II, which was conducted
between 10 July 2017 and 20 September 2017,
was to examine the tolerability of UV Fotogel
applied prior to sunbathing at the patients’
homes (Fig. 1). Two lesions were chosen for
each patient, and the size and L-PSI score of
each lesion were determined at baseline. The
patients were provided the UV Fotogel to be
applied and instructed to sunbathe for
15–30 min three to five times weekly between
8:30 am and 10:30 am or between 3:30 pm and
6:30 pm. Patients were instructed to apply UV
Fotogel to the chosen lesions and to apply a sun
protection preparation to the rest of the
exposed skin prior to sun exposure. The length
of time and other conditions of each sunbath
were recorded. The patient attended clinic visits
at 2-week intervals. The clinical study was ter-
minated when cessation of the desquamation
was observed. Enrollment in Part II of the study
was a minimum of 4 weeks and not longer than
6 weeks.
L-PSI, Cosmetic Acceptability,
and Tolerability
The L-PSI of each patient was evaluated by an
experienced dermatologist. The L-PSI score was
calculated by monitoring erythema, infiltration,
and desquamation and then scoring each of
these parameters with a score of 0 to 4 (0: not
present; 1: mild, 2: moderate; 3: severe; 4: very
severe).
Cosmetic acceptability was evaluated on a
5-point scale (1: poor; 2: sufficient; 3: good; 4:
very good; 5: excellent).
Patients were asked whether they experi-
enced any of the following symptoms: burning
sensations, stabbing pain, itching, stretching,
and tingling. These parameters of tolerability
were recorded on a 4-point scale (1: not present;
2: mild; 3: moderate; 4: severe).
Part I was a randomized and single-blind
study (the evaluating dermatologist was blinded
to the treatment sides), whereas Part II was an
open study.
Statistical Analysis
Statistical analysis was performed with the Sig-
maStat statistical software package for Windows
(Jandel Scientific, Erkrath, Germany). The Sha-
piro–Wilk test was used to check normality. The
values obtained varied significantly from the
pattern expected for a population with normal
distribution. Hence, non-parametric methods
were chosen for the comparison. The Wilcoxon
signed-rank test was applied to compare data
obtained before and after treatments, and the
Mann–Whitney rank sum test was used to ana-
lyze the differences between control and treated
sides. Median values are presented with the
25th and 75th percentiles (25p and 75p,
respectively). Statistical significance was set at
p\0.05.
RESULTS
In Part I, one patient left the study due to pro-
gression of the disease (systemic therapy was
required). Cessation of desquamation was
observed in three patients by the fourth visit.
The study was terminated for an additional nine
patients at visit 4, 18 patients at visit 5, and
eight patients at visit 6 as these patients had
L-PSI scores \ 4. With the exception of one
patient, the improvement leading to termina-
tion of the study was detected on the UV
Fotogel-treated side (Fig. 2).
In Part II, one patient decided to terminate
his enrollment after visit 2. Another patient quit
due to an adverse effect of the treatment
(burning sensation) but attended the final visit.
Desquamation had ceased in 40 patients by visit
3 and in the remaining four patients by visit 4
(Fig. 2).
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At the Final Visit, Application of UV
Fotogel Prior to NB-UVB Had Led
to Significantly Lower Scores for L-PSI,
Erythema, Infiltration, and Desquamation
on Treated Sides Compared to the Sides
Not Treated with UV Fotogel
The median L-PSI score for both sides at base-
line was 7.0 (25p–75p: 6.0–8.75). Compared to
the baseline score, there was a statistically sig-
nificant amelioration in median L-PSI scores on
both the control (NB-UVB only) and treated
(NB-UVB plus UV Fotogel) sides at the final
visit, but the median L-PSI score of the treated
side was significantly lower than that of the
control side (1.0 [25p–75p: 0.0–2.0] vs. 2.0
[1.0–3.0], respectively) (Fig. 3a).
The median erythema score at baseline was
2.0 (25p–75p: 2.0–3.0). Compared to the med-
ian baseline score, there was a statistically sig-
nificant reduction in this score on both the
control and treated sides at the final visit, but
the median erythema score of the treated side
was significantly lower than that of the control
side, indicating a greater decrease in erythema
(1.0 [25p–75p: 0.0–1.0] vs. 1.0 [1.0–1.0],
respectively) (Fig. 3b).
The median infiltration value after treatment
at visit 1 was 2.0 (25p–75p: 2.0–3.0). The med-
ian infiltration score at subsequent visits
decreased on both the treated and control sides,
Fig. 2 Flow chart of study progression and patient
distribution. a Part I, b Part II. V1, V2... V7 visit 1, visit
2, and all subsequent visits up to visit 7, Prog. progression
of the disease, Fin. number of patients finishing the study
at the given time due to cessation of desquamation or
Local Psoriasis Severity Index (L-PSI) score \ 4, AE
adverse event, VF final visit, Term Termination of the
study due to own decision
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however improvement of the skin, as indicated
by the median infiltration score, on the side
treated with UV Fotogel surpassed that of the
control side at the final visit (0.0
[25p–75p: 0.0–1.0] vs. 1.0 [0.0–1.0], respec-
tively) (Fig. 3c).
The median desquamation score at baseline
was 2.0 (25p–75p: 2.0–3.0). Compared to the
median baseline score, there was a statistically
significant reduction in this score on both the
control and treated sides at the final visit, but
the reduction, as indicated by the mean
desquamation score, was significantly greater
on the side treated with UV Fotogel than on the
control side (0.0 [25p–75p: 0.0–0.0] vs. 0.0
[0.0–1.0], respectively) (Fig. 3d).
Application of UV Fotogel With NB-UVB
Was Not Accompanied By Considerable
Adverse Effects and the Preparation Was
Found to be Cosmetically Acceptable
At the final visit, patients were asked to report
any adverse effects of using UV Fotogel. Two
patients reported a mild burning sensation,
three patients experienced mild itching, and
two patients experienced moderate itching.
Two patients reported mild stretching. None of
Fig. 3 Box plot of changes in the severity of psoriasis from
baseline to the final visit. Median and 25th and 75th
percentiles are shown. Asterisk indicates a significant
difference (*p\ 0.05 ) between values at baseline and
those at the final visit; the double S symbol indicates a
significant difference (§p\ 0.05) between the treated side
and the control side. a Changes in the L-PSI scores of
treated and control sides, b changes in erythema after
exposure to NB-UVB therapy with or without UV Fotogel
treatment, c effects of the phototherapy and the UV
Fotogel on infiltration, d values of desquamation of skin
with and without UV Fotogel application. See section ‘‘L-
PSI, Cosmetic Acceptability, and Tolerability’’ for descrip-
tion of scores
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the patients reported stabbing pain and tin-
gling. No severe symptoms were reported.
The majority of the patients (21 patients)
found the cosmetic acceptability of UV Fotogel
excellent, with ratings of very good and good
given by 11 and 11 patients, respectively. Only
one patient found the cosmetic acceptability
sufficient (Table 1).
Toleration to and Cosmetic Acceptability
of Applying UV Fotogel Prior
to Sunbathing
The use of UV Fotogel prior to sunbathing (Part
II of the study) led to a considerable decrease in
median L-PSI score, was well tolerated by the
patients, and the cosmetic acceptability was
assessed to be good.
The median L-PSI score of patients in Part II
at baseline (6.0 [25p–75p: 6.0–7.0]) had signifi-
cantly decreased by the final visit (2.5 [25p–75p:
1.5–3.5]). At the final visit, one patient reported
mild burning sensations and two patients
reported moderate burning sensations. One
patient experienced mild stabbing pain and
another experienced moderate stabbing pain.
Mild itch was reported by four patients and
moderate itch by three patients. One patient
felt mild stretching of the skin, and another
patient reported moderate stretching of the
skin. No patients reported tingling sensations.
Six patients considered the cosmetic accept-
ability to be excellent, 15 patients found it to be
very good, 18 patients evaluated it as good, and
six patients found it to be sufficient (Table 2).
DISCUSSION
The treatment of psoriasis depends on the
severity of the disease. In mild to moderate
Table 1 Tolerability, irritability, and cosmetic acceptability of UV Fotogel application in combination with narrow band-
ultraviolet B phototherapy
Tolerability and irritability of UV Fotogel with NB-UVB phototherapy
Degree of the symptoma Symptoms
Burning Stabbing pain Itching Stretching Tingling
1 42 (95.5%) 44 (100%) 39 (88.6%) 42 (95.5%) 44 (100%)
2 2 (4.5%) 0 (0%) 3 (6.8%) 2 (4.5%) 0 (0%)
3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Cosmetic acceptability
Scoreb n (%)
1 0 (0%)
2 1 (2.3%)
3 11 (25%)
4 11 (25%)
5 21 (47.7%)
Values in table are presented as the number of patients, with the percentage of the reporting population given in parenthesis
NB-UVB Narrow band-ultraviolet B
a 1, The given symptom is not present; 2, mild symptoms; 3, moderate symptoms; 4, severe symptoms. Note: no patient
reported moderate or severe symptoms
b 1, Poor acceptability; 2, sufficient; 3, good; 4, very good; 5, excellent
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psoriasis, topical therapy is indicated alone or in
combination with UV phototherapy.
NB-UVB is currently the first-line pho-
totherapy for stable plaque psoriasis. Compared
to broadband UVB phototherapy, NB-UVB
results in a faster reduction of lesions, with
longer remissions expected [10]. Nevertheless,
careful design of the therapy is necessary, as UV
light might lead to cataracts, photodermatitis,
and photoaging. Carcinogenesis is also a
potential risk [18]. However, the efficacy of UVB
therapy can potentially be increased by com-
bining it with different topical and systemic
agents. Historically, UVB phototherapy was
combined with coal tar; however, this prepara-
tion smells, stains skin, has irritative and car-
cinogenic properties, and may block UVB rays.
Dithranol has also applied to the skin to
improve the efficacy of UVB therapy, but this
preparation is associated with an increased risk
of irritation [19]. Other topical treatments used
just before UV irradiation (e.g., different emol-
lients, ichthyol, and calcipotriol) block the
penetration of UV light, thereby decreasing the
therapeutical efficacy of the phototherapy
[20–22]. In the present study, we combined NB-
UVB with a preparation which, when used
alone, does not have a therapeutic effect, but
which may enhance the efficacy of
phototherapy.
The optical properties of the psoriatic skin
differ from those of normal skin [17, 23]. The
multiple air–keratin interfaces in psoriatic scales
allow reflection and refraction of incident radi-
ation, and the lesions, thereby, act as a partial
optic barrier. Successful treatment of psoriasis
with UV-light requires adequate penetration of
the radiation to at least the level of viable epi-
dermal cells.
Compared to other combination therapies,
there appear to be fewer possibilities to modify
the transmission of UVB. A saltwater shower
and application of lipophilic compounds may
be beneficial [19, 24]. These latter compounds
reduce the fraction of incident radiation which
is then backscattered or re-emitted from the
Table 2 Tolerability, irritability, and cosmetic acceptability after application of UV Fotogel with sunbathing
Tolerability and irritability of UV Fotogel with sunbathing
Degree of the symptoma Symptoms
Burning Stabbing pain Itching Stretching Tingling
1 42 (93.3%) 43 (95.6%) 38 (84.4%) 43 (95.6%) 45 (100%)
2 1 (2.2%) 1 (2.2%) 4 (8.9%) 1 (2.2%) 0 (0%)
3 2 (4.4%) 1 (2.2%) 3 (6.7%) 1 (2.2%) 0 (0%)
Cosmetic acceptability
Scoreb n (%)
1 0 (0%)
2 6 (13.3%)
3 18 (40%)
4 15 (33.3%)
5 6 (13.3%)
Values in table are presented as the number of patients, with the percentage of the reporting population given in parenthesis
a 1, The given symptom is not present; 2, mild symptoms; 3, moderate symptoms; 4, severe symptoms. Note: no patient
reported moderate or severe symptoms
b 1, Poor acceptability; 2, sufficient; 3, good; 4, very good; 5, excellent
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skin. It has been confirmed in vivo that the
application of non-photosensitizing oily lubri-
cants to the skin increases the transmission of
light through psoriatic plaques, resulting in
increased effectivity of the phototherapy
[15, 17, 23]. Mineral oil (e.g., liquid paraffin)
can penetrate and fill the air–stratum corneum
interfaces, thereby facilitating the transmission
of radiation. It is currently the only Medicare-
approved treatment to increase the efficacy of
UVB phototherapy in the USA. However, the
majority of psoriasis treating centers have
reported that they do not routinely use emol-
lients before UV irradiation [16].
The lack of randomized controlled studies on
the benefit of using emollients concomitantly
with UVB is a further difficulty. The only clini-
cal investigation performed to date was con-
ducted with paraffin oil in children. This study
reported a significantly greater improvement in
scaling, induration, and area of involvement
after application of mineral oil while no adverse
effects were observed [16]. Nevertheless, min-
eral oil is considered to be cosmetically
unfavorable.
Although mineral oil stains clothes and
patients encounter difficulties in dressing after
the treatment, UVB with mineral oil is the most
frequently used phototherapy for psoriasis in
the USA according to an analysis of Healthcare
Common Procedure Coding System (HCPCS)
codes. In 2015, approximately 400,000 UVB
therapy treatments with mineral oil (HCPCS
code 96910) were performed in the USA, and
the corresponding USD 21.7 million cost
accounted for 48% of the total Medicare budget
for phototherapy [25]. Other emollient prepa-
rations (e.g., tar, salicylic acid, thickly applied
petrolatum) are cosmetically more favorable,
but have the disadvantages of absorbing UV
light, increasing MED, and slowing the clear-
ance of psoriasis [15, 26, 27].
The components of the UV Fotogel were
selected solely on their optical properties, as the
aim was to develop a medical device that
decreases the reflection of UVB light while at
the same time blocks the shorter wavelengths.
The absorption spectra of different compounds
and the UV transmittance through the gel were
measured in vitro [28]. Based on the results of
our previous in vitro examination, the compo-
nents of UV Fotogel facilitate the penetration of
UVB wavelengths in the 310- to 320-nm range
into the skin and block wavelengths in the
range of 280–300 nm [28]. Thus, the prepara-
tion facilitates penetration of the therapeuti-
cally useful fraction and blocks the range which
may evoke an inflammatory reaction (Fig. 4).
Moreover, topical use of the listed components
can be considered safe [29–31]. The findings of
the present study confirm the beneficial effect
of the preparation. After exposure to NB-UVB,
L-PSI values were found to be significantly lower
in UV Fotogel-treated lesions than in skin not
treated with UV Fotogel. Moreover, each
parameter of the L-PSI (erythema, infiltration,
and desquamation) showed a considerable
improvement with the application of UV Foto-
gel compared to the control skin. In addition to
the beneficial therapeutic effect, the prepara-
tion was well tolerated, and the cosmetic
acceptability was good.
Further interesting results were provided by
Part II, in which UV Fotogel was used by
patients prior to sunbathing. Although sun-
bathing is not considered to be a first-line
therapy in psoriasis [10], UV radiation from the
sun is an effective and natural treatment for the
disease [32]. The results from this part of the
study confirm that the preparation is cosmeti-
cally favorable and free of considerable adverse
reactions under the circumstances of home
application.
The limitations of our study include the rel-
atively low number of enrolled patients in Part I
and the lack of dosimetry in Part II.
Regarding the applicability of the results in
the general population, worldwide approxi-
mately 200 million patients have only mild
psoriasis that is frequently treated by natural
sunlight. However, no approved medical device
is as yet available to increase the transmittance
of UVB light by reducing the reflectance of the
sunlight. Since UV Fotogel allows and enhances
the penetration of therapeutically useful wave-
lengths (310–320 nm) and blocks the most ery-
thematogenic part of the UVB spectrum below
300 nm, this medical device may improve the
therapeutic effects of natural sunlight in mil-
lions of affected individuals.
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Although the preparation has been primarily
designed for the treatment of psoriasis, the
treatment of other diseases that are responsive
to UV therapy (e.g., atopic dermatitis, early-
stage cutaneous T-cell lymphoma) might possi-
bly also be enhanced with UV Fotogel. How-
ever, further investigation is necessary to
determine this.
CONCLUSIONS
In conclusion, application of a novel prepara-
tion containing sodium hyaluronate and nico-
tinic acid prior to NB-UVB phototherapy led to
a greater reduction of psoriatic lesions than NB-
UVB phototherapy alone. Furthermore, the
cosmetic acceptability of the preparation was
good, and there were no reports of considerable
side effects. The preparation was also well tol-
erated by patients who used it prior to sun-
bathing. The results suggest that UV Fotogel
might be a useful device for the enhancement of
phototherapy in psoriasis.
ACKNOWLEDGEMENTS
We thank the participants of the study.
Funding. The journals rapid Service Fee is
funded by the research Grant EFOP-3.6.2-16-
2017-00009 provided by the European Union
and the Hungarian Government and by the
EU’s H2020 Grant Agreement No. 739593.
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole, and have given their
approval for this version to be published.
Authorship Contributions. Lajos Keme´ny
and Eszter Balta´s are shared last authors.
Disclosures. Lajos Keme´ny has an approved
patent on the components of UV Fotogel.
Bala´zs Bende, Ro´bert Kui, Annama´ria Ne´meth,
Mariann Borsos, Zolta´n To´bia´s, Ga´bor Er}os and
Eszter Balta´s have nothing to disclose.
Compliance with Ethics Guidelines. The
study was approved by the National Institute of
Pharmacy and Nutrition (Hungary) (permission
numbers: OGYE´I/723/2017 and OGYE´I/28552/
2017) and was performed in accordance with
the Helsinki Declaration of 1964 and its later
amendments. Informed consent was obtained
from all participants.
Data Availability. The datasets generated
and analyzed during the current study are
available from the corresponding author on
reasonable request.
Fig. 4 Penetration of UVB radiation into the skin without (a) and with the use of UV Fotogel (b)
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